Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524713-88-00

Enrollment

Registered

2026-06-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Brief summary

Investigator’s determination of ongoing clinical benefit

Detailed description

Frequency and severity of side effects, including abnormal findings from laboratory tests or physical examinations

Interventions

DRUGVS-6063

DRUGVS-6766

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Investigator’s determination of ongoing clinical benefit	—

Secondary

Measure	Time frame
Frequency and severity of side effects, including abnormal findings from laboratory tests or physical examinations	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 23, 2026